Andrew Hirsch

Andrew Hirsch, MBA, is President and Chief Executive Officer, and a member of the Board of Directors, of C4 Therapeutics, a clinical-stage biotechnology company developing targeted protein degraders for oncology and non-oncology indications. Mr. Hirsch has more than 25 years of experience, having held an array of strategic and operating roles in the biotechnology sector. Before joining C4T in 2020, he was CFO and Head of Corporate Development at Agios Pharmaceuticals, Inc. Prior to Agios he was president and CEO of BIND Therapeutics, CFO at Avila Therapeutics, Inc. (which was acquired by Celgene Corp.) and held roles of increasing responsibility at Biogen Inc., including Vice President of Corporate Strategy and M&A and where he was program executive for the Tecfidera development team. Mr. Hirsch currently serves on the Board of Directors of Editas Medicine, Inc.

He holds an MBA from the Tuck School at Dartmouth College and a B.A. in economics from the University of Pennsylvania.